AstraZeneca and PTC Therapeutics announce strategic oncology drug discovery collaboration with potential extension to other therapeutic areas

Wednesday, 29 June 2011

AstraZeneca and PTC Therapeutics, Inc. (PTC) today announced that they have entered into an exclusive research collaboration and license agreement for the application of PTC’s proprietary GEMS™ technology (Gene Expression Modulation by Small-molecules) for the discovery and development of potential new therapies for cancer and other diseases for which there is a great unmet medical need.

Read more

Download our brochure

Download your comprehensive guide to partnering with us.


Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar